4th Quarter - Termination

CELGENE CORPORATION for CELGENE CORPORATION

Period 4th Quarter 2019 Filed Jan 21, 2020 Signed by Patrick Ghila

Official filing
Firm
CELGENE CORPORATION
Client
CELGENE CORPORATION
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Dec 31, 2019

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

LobbyistCovered position, as disclosed
GREG CHESMORE —
STEPHEN RUBRIGHT —
ALANNA TEMME —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 741 (116th), S. 2546 (116th), H.R. 2279 (116th), H.R. 1730 (116th), H.R. 965 (116th), S. 2543 (116th), S. 340 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.